Leadership 2018-05-07T09:18:47+00:00

Andrew Way
Professor Andrew Way
Chair, Governance Group, Monash Partners Comprehensive Cancer Consortium, Chief Executive, Alfred Health

Professor Way has served as Alfred Health’s Chief Executive since 2009. He is an Adjunct Clinical Professor at Monash University’s Faculty of Medicine, Nursing and Health Sciences, Director of  other health related organisations and is a member of several government and other advisory groups.Professor Way led the development of Victoria’s first Academic Health Science Centre – Monash Partners, which was accredited as an NHMRC Advanced Health and Research Translation Centre in 2015.  His focus is on improving access, ensuring high quality, safe services with low mortality, within a strong financial framework and a research-supportive environment.

Gail Risbridger
Professor Gail Risbridger
Research Director, Monash Comprehensive Cancer Consortium (MCCC) and Monash Partners Comprehensive Cancer Consortium (MPCCC); Head Prostate Cancer Research Group, Monash University

Professor Risbridger played an integral role in the establishment of the Monash Partners Comprehensive Cancer Consortium. She is a National Health and Medical Research Council (NHMRC) research fellow and a career academic and researcher with more than 20 years’ experience in prostate cancer research and men’s health.

Eva Segelov

Professor Eva Segelov
Acting Clinical Director, Southern Melbourne Integrated Cancer Service, Professor Director of Oncology, Monash Health and Monash University

Professor Eva Segelov is a recognised national and international expert in the fields of gastrointestinal cancer, neuroendocrine tumours, and breast cancer, with a 20 year history of management of patients in a multidisciplinary setting. Professor Segelov has led multiple national and international oncology clinical trials, including investigator-initiated studies. Her research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce the toxicity of cancer treatments.

John Zalcberg
Professor John Zalcberg OAM
Monash Partners Cancer and Blood Diseases Theme representative, Head, Cancer Research Program, School of Public Health and Preventive Medicine, Monash University, Tony Charlton Chair of Oncology, The Alfred

Professor Zalcberg’s clinical research interests include gastrointestinal cancer and health care outcomes.  He leads projects in Clinical Quality Registries that collect patient outcome data for lung, ovarian and Upper GI cancers. He has an active involvement in clinical trials in GI cancers and continues an active clinical practice in GI cancer. Professor John Zalcberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position.